Camlin Fine Sciences (532834) Hisse Özeti
Camlin Fine Sciences Limited, iştirakleriyle birlikte Hindistan'da ve uluslararası alanda özel kimyasalların, bileşenlerin ve katkı karışımı ürünlerin araştırılması, geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camlin Fine Sciences Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹136.70 |
| 52 Haftanın En Yüksek Seviyesi | ₹311.90 |
| 52 Haftanın En Düşük Seviyesi | ₹96.30 |
| Beta | 0.64 |
| 1 Aylık Değişim | 1.26% |
| 3 Aylık Değişim | 33.05% |
| 1 Yıllık Değişim | -55.22% |
| 3 Yıllık Değişim | -15.75% |
| 5 Yıllık Değişim | -34.06% |
| Halka arzdan bu yana değişim | 1,508.24% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Anlatı Güncellemesi • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Anlatı Güncellemesi • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Recent updates
Anlatı Güncellemesi • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Anlatı Güncellemesi • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Anlatı Güncellemesi • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Anlatı Güncellemesi • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Anlatı Güncellemesi • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Anlatı Güncellemesi • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Anlatı Güncellemesi • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Anlatı Güncellemesi • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Anlatı Güncellemesi • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Anlatı Güncellemesi • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Anlatı Güncellemesi • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Yeni Anlatı • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Hissedar Getirileri
| 532834 | IN Chemicals | IN Pazar | |
|---|---|---|---|
| 7D | 0.3% | 1.9% | 1.0% |
| 1Y | -55.2% | -4.7% | -1.4% |
Getiri vs. Endüstri: 532834 geçen yıl % -4.7 oranında getiri sağlayan Indian Chemicals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 532834 geçen yıl % -1.4 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.7% |
| Chemicals Industry Average Movement | 6.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
İstikrarlı Hisse Senedi Fiyatı: 532834 hisse senedi fiyatı, son 3 ayda Indian piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: 532834 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala Indian hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1931 | 661 | Ashish Dandekar | www.camlinfs.com |
Camlin Fine Sciences Limited, iştirakleriyle birlikte Hindistan'da ve uluslararası alanda özel kimyasalların, bileşenlerin ve katkı karışımı ürünlerin araştırılması, geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir. Şirket, Butylated Hydroxy Toluene ve Ascorbyl palmitate içeren antioksidanlar ve Xtendra ve NaSure markaları altında raf ömrünü uzatmak için kullanılan karışık tokoferoller, yeşil çay özü ve biberiye özü gibi bitki bazlı antioksidanların yanı sıra emülgatörler, küf önleyiciler, antibakteriyel ajanlar, toksin bağlayıcılar, pelet bağlayıcılar, dezenfektanlar, enerji vericiler, koruyucular, kıvam arttırıcılar ve büyüme destekleyicileri içeren raf ömrü çözümleri sunmaktadır. Ayrıca vanilin ve etil vanilin gibi aroma bileşenleri; sağlık ve zindelik ürünleri; hidrokinon ve kateşol gibi performans kimyasalları da sağlamaktadır.
Camlin Fine Sciences Limited Temel Bilgiler Özeti
| 532834 temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹26.26b |
| Kazançlar(TTM) | -₹274.47m |
| Gelir(TTM) | ₹17.23b |
1.5x
P/S Oranı-95.7x
F/K Oranı532834 aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| 532834 gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹17.23b |
| Gelir Maliyeti | ₹9.22b |
| Brüt Kâr | ₹8.01b |
| Diğer Giderler | ₹8.28b |
| Kazançlar | -₹274.47m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.43 |
| Brüt Marj | 46.47% |
| Net Kâr Marjı | -1.59% |
| Borç/Özkaynak Oranı | 66.8% |
532834 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/05 08:53 |
| Gün Sonu Hisse Fiyatı | 2026/07/03 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Camlin Fine Sciences Limited 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |